Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Targanta Therapeutics Corp.

Division of The Medicines Co.
www.targanta.com

Latest From Targanta Therapeutics Corp.

Appointments: IRX Therapeutics, Therachon, Mission Therapeutics and bluebird bio

This week’s roundup includes CEO appointments by Smart Matrix and IRX Therapeutics, with various senior level appointments by companies including Therachon, Mission Therapeutics and bluebird bio.

Appointments BioPharmaceutical

Chiasma names new CEO

Chiasma, a US privately held biopharma company developing octreotide capsules for the orphan condition acromegaly, has appointed Mark Leuchtenberger president and CEO. Mr Leuchtenberger brings 25 years of industry experience to Chiasma, including CEO positions with Acusphere, Rib-X Pharmaceuticals, Targanta Therapeutics and Therion Biologics. From 1996 to 2002, he held multiple senior positions with Biogen, where he managed North American and international commercial operations. He currently serves as advisory board chair of the Massachusetts Emerging Technology Fund, MassDevelopment, and as a trustee and member of the Medical Education Committee, Beth Israel Deaconess Medical Center. And is also a board member of the Massachusetts Biotechnology Council.

Metabolic Disorders Israel

FDA gives MDCO's ABSSSI drug oritavancin 2nd chance

If all goes according to schedule, The Medicines Company (MDCO) could have a decision in hand by 6 August for its new drug application (NDA) for oritavancin, an investigational intravenous antibiotic the firm is seeking approval for as a single-dose treatment for acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).

Cardiovascular Infectious Diseases

Oritavancin Phase III Results Support FDA’s New Endpoint, Sponsor Says

FDA’s new early endpoint for efficacy in ABSSSI had been criticized at the time it was released. But reporting positive results for a second Phase III study of oritavancin, The Medicines Co. CEO says the agency’s ABSSSI endpoints are “appropriate” for industry.

BioPharmaceutical Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Infectious & Viral Diseases
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • PhageTech Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • The Medicines Co.
  • Senior Management
  • George A Eldridge, SVP, Fin. & Admin. & CFO
    Ron Wickline, VP, Sales
    Gayle Crick Fischer, VP, Mktg.
    Pierre E.G. Etienne, MD, Chief Dev. Officer
  • Contact Info
  • Targanta Therapeutics Corp.
    Phone: (617) 577-9020
    222 Third St., Ste. 2300
    Cambridge, MA 02142
    USA
UsernamePublicRestriction

Register